NeoSep1 Trial for Neonatal Sepsis
In July 2026, the NeoSep1 international clinical trial expanded to India, with the first newborn enrolled at JIPMER, Puducherry, to evaluate effective antibiotic combinations for treating drug-resistant neonatal sepsis.
- The trial is sponsored by the Global Antibiotic Research and Development Partnership (GARDP) in collaboration with international partners.
- The study evaluates safe, effective, and affordable antibiotic combinations for treating neonatal sepsis caused by antimicrobial-resistant (AMR) pathogens.
- Neonatal sepsis is a life-threatening bloodstream infection occurring in infants below 90 days of age, particularly premature and low-birth-weight ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Science & Technology
- 1 Indian Researchers Develop Placenta-on-Chip
- 2 INS Malvan
- 3 Vikram-1: India's First Private Orbital Rocket
- 4 Euclid Telescope Discovers the Oldest Known Quasars
- 5 Indian Researchers Develop New Method to Model the Topside Ionosphere
- 6 NASA’s Swift Boost Mission
- 7 ISRO Tests SOLVE Solid Motor
- 8 INS Mahendragiri Joins Indian Navy
- 9 ISRO Conducts Three Gaganyaan Tests
- 10 FCC Approves Sunlight Reflection Satellite
